Dr. Joel W Neal M.D., PH.D.
Hematologist-Oncologist | Hematology & Oncology
875 Blake Wilbur Dr Room Cc 2220 Stanford CA, 94305Rating
5/5
About
Dr. Joel Neal is a hematologist oncologist practicing in Stanford, CA. Dr. Neal specializes in the diagnosis, treatment and prevention of blood diseases such as anemia, hemophilia, sickle-cell disease, leukemia and lymphoma. Hematologist Oncologists are also trained in the study of cancer and its attack on other organs.
Education and Training
Feinberg School of Medicine - Northwestern University 2004
Board Certification
Internal MedicineAmerican Board of Internal MedicineABIM- Medical Oncology- 2010
Internal MedicineAmerican Board of Internal MedicineABIM- 2007
Provider Details
Expert Publications
Data provided by the National Library of Medicine- Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells.
- A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts.
- Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells.
- Histology matters: individualizing treatment in non-small cell lung cancer.
- The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer.
- Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.
- First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.
- Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.
- A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.
- Review of the current targeted therapies for non-small-cell lung cancer.
- Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
- Management of Dermatologic Complications of Lung Cancer Therapies.
- Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
- Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.
Clinical Trials
Treatments
- Thoracic Cancer, Lung Cancer
Fellowships
- Dana-Farber Cancer Institute MA 2010
- Dana Farber Cancer Institute 2010
Publications
- JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKA Patient With Aplastic Lymphoma Kise-Positive Non2013
- JOURL OF THORACIC ONCOLOGYA Case Series of NSCLC Patients with Different Molecular Characteristics2013
- Jourl of thoracic oncologyTargeting fibroblast growth factor receptor2012
- JOURL OF THORACIC ONCOLOGYA Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer2012
- JOURL OF CLINICAL ONCOLOGYComplex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer2012
- JOURL OF CLINICAL ONCOLOGYIpilimumab in Combition With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB2012
- CLINICS IN CHEST MEDICINECurrent Magement of Small Cell Lung Cancer2011
- JOURL OF THORACIC ONCOLOGYTargeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer2011
- FUTURE ONCOLOGYThe SATURN trial: the value of maintence erlotinib in patients with non-small-cell lung cancer2010
- Jourl of thoracic oncologyCetuximab monotherapy in patients with advanced non2010
- ture reviews. Clinical oncologyTargeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.2010
- Clinical advances in hematology & oncology : H&OFirst-line use of EGFR tyrosine kise inhibitors in patients with NSCLC containing EGFR mutations.2010
- BLOODInduction of FucT-VII by the Ras/MAP kise cascade in Jurkat T cells2003
- JOURL OF BIOLOGICAL CHEMISTRYA constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts2003
- JOURL OF BIOLOGICAL CHEMISTRYCalcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells2002
- JOURL OF BIOLOGICAL CHEMISTRYGlycogen synthase kise-3 inhibits the D binding activity of NFATc2001
- JOURL OF BACTERIOLOGYREGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE1994
- Clinical lung cancerA Case Series of Lengthy Progression-Free Survival With Pemetrexed2013
- JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKA Patient With Anaplastic Lymphoma Kinase-Positive Non2013
- JOURNAL OF THORACIC ONCOLOGYA Case Series of NSCLC Patients with Different Molecular Characteristics2013
- EXPERT OPINION ON BIOLOGICAL THERAPYAflibercept in lung cancer2013
- Journal of thoracic oncologyTargeting fibroblast growth factor receptor2012
- JOURNAL OF THORACIC ONCOLOGYA Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer2012
- JOURNAL OF CLINICAL ONCOLOGYComplex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer2012
- JOURNAL OF CLINICAL ONCOLOGYIpilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB2012
- Biologics : targets & therapyFirst-line treatment of EGFR-mutant non-small-cell lung cancer2012
- CLINICS IN CHEST MEDICINECurrent Management of Small Cell Lung Cancer2011
- JOURNAL OF THORACIC ONCOLOGYTargeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer2011
- CLINICAL CANCER RESEARCHOne Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer2011
- FUTURE ONCOLOGYThe SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer2010
- Journal of thoracic oncologyCetuximab monotherapy in patients with advanced non2010
- CURRENT OPINION IN MOLECULAR THERAPEUTICSAMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer2010
- CURRENT TREATMENT OPTIONS IN ONCOLOGYExciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh2010
- Nature reviews. Clinical oncologyTargeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.2010
- Clinical advances in hematology & oncology : H&OFirst-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.2010
- BLOODInduction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells2003
- JOURNAL OF BIOLOGICAL CHEMISTRYA constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts2003
- JOURNAL OF BIOLOGICAL CHEMISTRYCalcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells2002
- JOURNAL OF BIOLOGICAL CHEMISTRYGlycogen synthase kinase-3 inhibits the DNA binding activity of NFATc2001
- JOURNAL OF BACTERIOLOGYREGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE1994
Experience & Accolades
- Assistant Professor of Medicine (Oncology)the Stanford University Medical Center
Dr. Joel W Neal M.D., PH.D.'s Practice location
Joel Neal
875 Blake Wilbur Dr Room Cc 2220 -Stanford, CA 94305Get Direction
Dr. Joel W Neal M.D., PH.D.'s reviews
Write ReviewPatient Experience with Dr. Neal
Recommended Articles
![]()
New Study Discovers How Lymphoma Affects Survivors’ Ability to WorkYoung adults in many countries pride themselves on their work. They have worked hard to get to where they are and there is a huge sense of accomplishment in joining the adult world and being able to provide for themselves and their new families if applicable. When cancer comes along, their ability...
![]()
Living as a Hodgkin Lymphoma Survivor: Creating a New NormalNo one can ever truly be prepared for what it is like to live with cancer. Even the strongest survivors face setbacks, and some of the fiercest warriors share their stories of how they find their "new normals."Kimberly's storyWhen she was only 25, just five days before her wedding, Kimberly felt a...
![]()
The Lymphoma Research Foundation's Light it Red for Lymphoma NightLymphoma, a cancer of the lymphatic system, currently affects over 700,000 Americans who are living with or in remission from the disease. Statistics show that every seven minutes, someone in the United States is diagnosed with the condition, which amounts to approximately 80,000 people per year.The...
![]()
What are the Stages of Multiple Myeloma?This is the uncommon type of cancer that forms in plasma cells. A type of white blood cells found in the body, plasma cells, identify and battle germs and infections that attack the body.In multiple myeloma patients, the healthy plasma cells are overtaken by cancer cells. This reduces the number of...
![]()
Black Sabbath's Tony Iommi Discusses Struggles with LymphomaTony Iommi is one of the few rock and roll legends who can say that they fulfilled the industry’s cliché act of getting the band back together. In 2011, the loss of a good friend brought the Black Sabbath guitarist Iommi back into contact with the band’s original lead vocalist, Ozzy Osbourne....
![]()
Morphos Declared a "Breakthrough Therapy" for LymphomaMorphoSys’s main objective is to design exceptional and unique biopharmaceuticals, all designed to enhance the lives of patients suffering from severe or life-threatening conditions.The human body has two types of lymphocytes that can develop into lymphomas: B lymphocytes (B cells) and T...
Nearby Providers
![]()
Thorsten Graef995 East Arques Avenue Sunnyvale California 94085![]()
Dr. Ostap G Melnyk MD13847 E 14th St San Leandro CA 94578![]()
Dr. Peter Samuel Galatin M.D., PH.D.2585 Samaritan Dr San Jose CA 95124![]()
Dr. Joseph Andrew Mollick M.D.875 Blake Wilbur Drive, Mc5820 Stanford CA 94305![]()
Dr. Alexander Dimitrios Colevas MD875 Blake Wilbur Drive Stanford CA 94305![]()
Dr. Rondeep Singh Brar M.D.300 Pasteur Dr Palo Alto CA 94304
Nearest Hospitals
STANFORD HEALTH CAREl
300 PASTEUR DRIVE STANFORD CA 94305MENLO PARK SURGICAL HOSPITALl
570 WILLOW ROAD MENLO PARK CA 94025LUCILE SALTER PACKARD CHILDREN'S HSP AT STANFORDl
725 WELCH ROAD PALO ALTO CA 94304